Roth MKM initiated coverage of Reviva Pharmaceuticals (RVPH) with a Buy rating and $7 price target The firm says its optimism is driven by brilaroxazine’s positive Phase 3 data demonstrating its impact on positive, negative and cognition symptoms in schizophrenia patients with an effect size greater than many antipsychotics. The “unequivocal” Phase 3 results underscore Reviva’s “de-risked clinical strategy,” the analyst tells investors in a research note.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals Strengthens Financial Position with Offering
- Reviva Pharmaceuticals 12M share Spot Secondary priced at $1.50
- Reviva Pharmaceuticals announces common stock, warrant offering, no amount given
- Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results
- Reviva announces topline data for OLE portion of Phase 3 RECOVER study